FP-101

DRUG3 trials

Sponsors

Onyx Therapeutics, Inc., Fervent Pharmaceuticals

Conditions

Hot FlashesMenopauseMultiple myeloma MedDRA version: 12.1 Level: LLT Classification code 10028228 Term: Multiple myelomaVasomotor Symptoms

Phase 2

FP-101 for the Treatment of Hot Flashes in Postmenopausal Women

CompletedNCT03285672

Fervent PharmaceuticalsHot Flashes

Start: 2018-03-26End: 2018-10-29Updated: 2018-11-01

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

CompletedNCT05312567

Fervent PharmaceuticalsMenopause, Vasomotor Symptoms

Start: 2021-03-24End: 2023-07-31Updated: 2023-10-26

Unknown Phase

A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma

Active, not recruitingEUCTR2009-016840-38-AT

Onyx Therapeutics, Inc.Multiple myeloma MedDRA version: 12.1 Level: LLT Classification code 10028228 Term: Multiple myeloma

Start: 2010-04-22Target: 84Updated: 2015-09-28